0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover267.98%IV-39.57%PremiumSep 20, 2024Expiry Date11.46Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9755Delta0.0072Gamma2.51Leverage Ratio-0.0517Theta0.0018Rho2.45Eff Leverage0.0017Vega
Spyre Therapeutics Stock Discussion
U.S. stocks advanced on Monday, building off a record finish ahead of the ramping up of fourth-quarter earnings season.
The $Dow Jones Industrial Average (.DJI.US)$ rose 138 points, or 0.26%, to 38,000. The $S&P 500 Index (.SPX.US)$ was up 10 points, or 0.22%, at 4,850. The $Nasdaq Composite Index (.IXIC.US)$advanced 49 points, or 0.32%, to 15,360.
While the S&P 500 finally returned to record territory on Friday, skeptic...
Spyre felt the positive pressure from fresh buy ratings by analysts like Stifel. $Ginkgo Bioworks (DNA.US)$ also roase 9%, despite a new sell rating from Goldman Sachs.
But monday morning was not al...
No comment yet